Medical Cannabis for Chronic Pain in Canada: What the Evidence Actually Says

Chronic pain is one of the most common reasons Canadians ask about medical cannabis. It is also the area where the gap between what people have heard and what the research shows is widest.

This article sets out what the clinical guidelines actually recommend, how large the benefit realistically is, and how access works in Canada. It is not a sales pitch. If the honest answer for your situation is that cannabis is unlikely to help much, that is worth knowing before you spend money on it.

What chronic pain is

Chronic pain is generally defined as pain that persists or recurs for three months or more. It affects roughly one in five people, and is more common in women, in older adults, in veterans, in Indigenous populations, and among people who are socioeconomically disadvantaged.

It is not simply long-lasting acute pain. Over time the nervous system itself changes, which is part of why treatments that work for a broken bone often do little for pain that has lasted years.

Where cannabinoids fit: the mechanism

The body has its own endocannabinoid system, which is involved in regulating pain signalling, mood, sleep and inflammation. Plant cannabinoids such as THC and CBD interact with this same system. Our guide to the differences between THC and CBD explains how the two behave differently, and our overview of CBN, CBD and CBG covers the less familiar cannabinoids.

That mechanism is why cannabis is studied for pain at all. It is not, by itself, evidence that it works well.

What the Canadian guidelines recommend

This is the part most articles skip.

The College of Family Physicians of Canada published a simplified guideline for prescribing medical cannabinoids in primary care. Its overall position is cautious: it recommends limiting medical cannabinoid use in general, while setting out a small number of conditions where there is some supporting evidence.

Those conditions are:

• Refractory neuropathic pain, meaning nerve pain that has not responded to other treatments
• Refractory pain in palliative care
• Chemotherapy-induced nausea and vomiting
• Spasticity in multiple sclerosis and spinal cord injury

The guideline also sets out a sequence. Before authorising cannabis for neuropathic pain, a clinician should first have adequately tried other pharmacological and non-pharmacological treatments, and then pharmaceutical cannabinoids.

In other words: within Canadian primary care guidance, cannabis is positioned as an option after conventional treatment has been genuinely tried, not as a first step.

How large is the benefit, honestly

An international clinical practice guideline published in the BMJ issued a weak recommendation in favour of trying non-inhaled medical cannabis for chronic pain. The panel described the recommendation as weak specifically because the balance between benefits and harms is close.

The scale of benefit is worth stating plainly. Summarising that evidence, commentary noted that where the evidence of benefit is moderately strong, roughly ten people need to be treated for one person to gain a one-point improvement in average pain score, with limited improvements in sleep and physical functioning.

Risks and trade-offs

Any honest discussion of benefit has to include the other side. Common adverse effects include dizziness, drowsiness, dry mouth, cognitive effects and impaired coordination. There are situations where cannabis is not appropriate at all, including a personal or strong family history of psychosis, current or past substance use disorder, pregnancy or breastfeeding, and cardiovascular disease.

Caution is also advised for people with a current mood or anxiety disorder, heavy alcohol users, and those taking opioids or benzodiazepines. If you take other medications, that interaction review is one of the main reasons to go through a practitioner rather than self-medicating.

Why the medical route matters for pain patients

• A practitioner assesses whether cannabis is appropriate for your specific pain type, since neuropathic pain has better supporting evidence than most other pain categories.
• Dosing is structured and gradual rather than trial and error.
• Products have known cannabinoid content. Our beginner’s guide to cannabinoid oil covers non-inhaled formats, which are the ones most guidelines discuss.
• Coverage becomes possible. See eligible for coverage and our article on whether health insurance covers medical cannabis.
• For long-term users, growing your own can reduce cost. The ACMPR licence guide explains how, and our article on Health Canada’s limits on daily amounts and plant counts covers the restrictions.

How to start in Canada

Access requires authorisation from a physician or nurse practitioner. Our complete guide to cannabis prescriptions in Canada covers eligibility, and the step-by-step prescription guide sets out what happens at each stage. Reading our article on mistakes to avoid when applying before you begin will save time. Ongoing clinical support is available through primary care.

Frequently asked questions

Next step

If you are living with pain that has lasted months or years and conventional treatment has not been enough, a consultation will tell you whether medical cannabis is a reasonable option for your specific type of pain, including if it is not. Apply now or contact our team.